Among the IDH inhibitors that have been evaluated in clinical trials of patients with AML, ivosidenib and enasidenib have been approved by the FDA for the treatment of IDH1- and IDH2-mutated disease, respectively65. The gene discussed is IDH1; the disease is acute myeloid leukemia.